Pharmacokinetic (PK) and Pharmacodynamic (PD) assays are the engine room for Lead Optimisation Drug Discovery.

With our combined years of extensive experience delivering programmes into preclinical development, we understand the need for robust, pharmacologically sensitive, high-throughput, multi-modal in-vivo and ex-vivo endpoints that can be put into context with drug exposure levels.

We offer PK/PD studies across a wide range of preclinical species, including mice, rats, cats and dogs, tailored to your program needs. Our capabilities cover virtually any dosing route, along with a broad range of behavioural endpoints and tissue/fluid collection services.

Examples of models we offer:

Behaviour / In-vivo

  • •
    Transgenic animals (rats and mice) to model specific mechanistic targets
  • •
    Temperature (rectal and microchipped)
  • •
    IRWIN
  • •
    Rotarod
  • •
    24/7 Circadian Rhythm
  • •
    LPS-induced inflammation (cytokine and chemokine release)
  • •
    Laser Doppler cutaneous blood flow
  • •
    Pharmaco EEG
  • •
    EMG
  • •
    Seizure models
  • •
    LABORAS automated complex behavioural assessment (locomotor activity, feeding, drinking, rearing, wet dog shakes, head twitch, grooming etc.)

Ex-vivo

  • •
    Systemic drug exposure
  • •
    CNS / peripheral target organ tissue drug exposure
  • •
    Cerebrospinal Fluid, (CSF) drug exposure
  • •
    Ligand Binding
  • •
    Biomarker assessment (RNA and Protein)
  • •
    PBMC stimulation (rodent and human)
  • •
    Blood glucose assessment
  • •
    Clinical Chemistry
  • •
    Neurochemisty